Skip to main content
Clinical Trials/NCT03362164
NCT03362164
Recruiting
N/A

Prospective Monocentric Cohort Study to Evaluate Predictors for Heart Failure and Sudden Cardiac Death in Patients With Fabry Disease

Wuerzburg University Hospital1 site in 1 country650 target enrollmentJanuary 2001

Overview

Phase
N/A
Intervention
Not specified
Conditions
Rare Diseases
Sponsor
Wuerzburg University Hospital
Enrollment
650
Locations
1
Primary Endpoint
Cardiac death
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

This study evaluates predictors for the incidence of arrhythmias and sudden cardiac death as well as terminal heart failure in patients with Fabry disease.

Detailed Description

Fabry disease is a rare disease and part of the group of lysosomal storage disorders. Natural history of Fabry disease has proven poor survival to ages \>50 years outlining the importance to evaluate cardiac symptoms and outcomes of patients with Fabry disease. This study is a prospective cohort study and observes patients since 2001. Through this long-term experience and the relative high number of patients this study is suggested to help estimating the risk of cardiac arrhythmias and sudden cardiac death (SCD) as well as death or heart transplantation due to terminal heart failure. All patients in treatment in the Fabry Center Wuerzburg (FAZiT) are included in this study if informed consent is provided.

Registry
clinicaltrials.gov
Start Date
January 2001
End Date
March 2032
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

PD Dr. Peter Nordbeck

Head Consultant Cardiology and Chief of Electrophysiology

Wuerzburg University Hospital

Eligibility Criteria

Inclusion Criteria

  • Fabry disease (genetically confirmed)
  • Signed informed consent
  • 18 years and older

Exclusion Criteria

  • No informed consent
  • Withdrawal of informed consent

Outcomes

Primary Outcomes

Cardiac death

Time Frame: From date of inclusion until the date of first documented event, up to the year 2032

Patients sustaining cardiac death

Secondary Outcomes

  • Heart transplantation(From date of inclusion until the date of first documented event, up to the year 2032)
  • Malign Arrhythmias(From date of inclusion until the date of death, up to the year 2032)

Study Sites (1)

Loading locations...

Similar Trials